Does Telix Pharmaceuticals have tremendous potential?

Team Veye | 02 Nov 2019 ASX - TLX

Telix Pharmaceuticals Limited (ASX.TLX)

Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Group”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularlytargeted radiation” (MTR), on 29 October 2019 provided a sales update for the TLX591-CDx (68Ga-PSMA11) kit, marketed in the United States as illumetTM (“Kit”).

A strong quarter of kit sales
Q3 Orders up by 20% over Q2
~8,200 patient doses produced YTD

(Chart source: TradingView)

Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer

Telix Pharmaceuticals Limited (ASX: TLX), announced on 30 October 2019 that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the treatment of ovarian and lung cancers.

The partnership will fund a first-in-human clinical trial using APOMAB technology to evaluate targeted radiation delivery in cancer patients at the RAH. APOMAB has the potential to be used for multiple cancer indications, with lung and ovarian cancers the initial focus. (Data Source – Company Reports)

Veye’s Take

Telix continues to make good progress globally developing a customer base for its prostate imaging product, in advance of its planned US/EU market launch in 2020. There is a growing appreciation of the quality and ease-of-use of the product, and opinion leader traction at the recent European Association of Nuclear Medicine (EANM) congress put a significant spotlight on its product development activity. The partnership with AusHealth will fund a first-in-human clinical trial using APOMAB technology to evaluate targeted radiation delivery in cancer patients at the RAH. APOMAB has the potential to be used for multiple cancer indications, with lung and ovarian cancers the initial focus. Targeted radiation has tremendous therapeutic efficacy in many different types of cancer. The APOMAB approach may enable the use of this treatment modality in several new cancer indications that are not currently covered by Telix’s pipeline. As reviewed earlier the stock has already cleared its strong resistance at $1.40 and now, after some consolidation, can go to $1.75, $2.05 and above. If it retraces, it could be providing a buying opportunity. We had recommended a “Buy” on “Telix Pharmaceutical Limited” at the price of $1.26 on 20.6.2019. It has already grown by more than 30% till now. Veye maintains a "Hold" on “Telix Pharmaceutical Limited” at the current price of $1.64

Disclaimer

Veye Pty Ltd (ABN 58 623 120 865) authorised representative (AR No. 001261006) of Vested Equities Pty Ltd which holds an Australian Financial Services License (AFSL No. 478987). Veye is authorised to share only generic financial views through its website, reports and newsletters without taking into consideration your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure the accuracy of the content and that the information is gathered and processed from reliable resources, it is recommended you seek professional advice from your financial advisor or stockbroker before acting on any of our recommendations. Veye Pty Ltd advises it’s users to pursue investing as a long-term goal. Stocks are subject to real time changes therefore all the information we share represents our views at the date of publishing and we request our readers not to interpret our reports as direct recommendations. Past performance is no indication of potential future performance. The securities and financial products we study and share information on in Veye Reports may have a product disclosure statement or other offer document associated with them. You should obtain a copy of these documents before making any decision about acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Veye Pty Ltd confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report (as mentioned on the website www.veye.com.au).